Skip to main content
Premium Trial:

Request an Annual Quote

Evotec, Ono Extend Drug Discovery Services Pact

NEW YORK (GenomeWeb News) – Evotec and Ono Pharmaceutical have extended a research collaboration and have struck a new agreement to study potential drug compounds, Evotec said today.

The companies began their drug target collaboration in March 2008.

Under the agreements, Evotec will provide high-throughput screening, in vitro pharmacology, protein crystallography, and medicinal chemistry services to discover small molecular weight compounds that will be used against an ion channel target. The aim of the collaboration is to move Ono's compound towards clinical development.

For its research services, Evotec will receive research funding and milestone payments, the Hamburg-based company said.

"We anticipate the collaboration will result in identifying a novel drug candidate with a high potential," Ono's Managing Director, Kazuhito Kawabata, said in a statement.

Specific financial terms of the agreement were not released.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.